UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of report (date of earliest event reported): November 26, 2016
 
 
INNOVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
000-52991
90-0814124
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
9171 Towne Centre Drive, Suite 440, San Diego, CA 92122
(Address of principal executive offices) (Zip Code)
 
 
Registrant’s telephone number, including area code: (858) 964-5123
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
Item 1.01   Entry into a Material Definitive Agreement.
 
On November 29, 2016, the Company announced that it had entered into an exclusive license and distribution agreement with J&H Co. LTD for the commercialization of Zestra® in South Korea. The exclusive 10-year agreement includes a minimum of $2 million per year in sales to the Company for a total of $20 million over the life of the agreement.
  
A copy of the press release regarding the above-described agreement is attached as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K.
 
Item 9.01   Financial Statements and Exhibits.
 
(d)            
Exhibits.
 
99.1             
Press Release issued November 29, 2016
 
 
 
 
 
 
 
2
 
 
SIGNATURE
 
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
INNOVUS PHARMACEUTICALS, INC.
 
 
 
 
 
Date: November 29, 2016
By:  
/s/  ROBERT E. HOFFMAN
 
 
 
Robert E. Hoffman
 
 
 
Executive Vice President and Chief Financial Officer
 
 
 
 
 
 
 
 
 
3